SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-051097
Filing Date
2023-06-23
Accepted
2023-06-22 20:12:46
Documents
12
Period of Report
2023-06-19
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea180833-8k_nektar.htm   iXBRL 8-K 25811
  Complete submission text file 0001213900-23-051097.txt   197259

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE nktr-20230619.xsd EX-101.SCH 2953
3 XBRL LABEL FILE nktr-20230619_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE nktr-20230619_pre.xml EX-101.PRE 22355
6 EXTRACTED XBRL INSTANCE DOCUMENT ea180833-8k_nektar_htm.xml XML 3491
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 231034667
SIC: 2834 Pharmaceutical Preparations